{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:01:38Z","timestamp":1776492098829,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijpharm.2021.120548","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T20:23:55Z","timestamp":1617049435000},"page":"120548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Fucoidan\/chitosan nanoparticles functionalized with anti-ErbB-2 target breast cancer cells and impair tumor growth in vivo"],"prefix":"10.1016","volume":"600","author":[{"given":"Catarina","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"C\u00e9line S.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Eduarda P.","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Nuno M.","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Rui L.","family":"Reis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-7432","authenticated-orcid":false,"given":"Bruno M.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Tiago H.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Albino","family":"Martins","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","article-title":"Molecular subtypes and local-regional control of breast cancer","volume":"27","author":"Fragomeni","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ijpharm.2021.120548_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.ijpharm.2021.120548_b0020","first-page":"17","article-title":"Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies","volume":"9","author":"Nounou","year":"2015","journal-title":"Breast Cancer: Basic Clin. Res."},{"key":"10.1016\/j.ijpharm.2021.120548_b0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ijpharm.2021.120548_b0030","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: a comprehensive review of the literature","volume":"2","author":"Bazak","year":"2014","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsps.2017.10.012","article-title":"Applications of nanoparticle systems in drug delivery technology","volume":"26","author":"Rizvi","year":"2018","journal-title":"Saudi Pharmac. J."},{"issue":"2","key":"10.1016\/j.ijpharm.2021.120548_b0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles: applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrc3180","article-title":"Treating metastatic cancer with nanotechnology","volume":"12","author":"Schroeder","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijpharm.2021.120548_b0050","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/srep02534","article-title":"Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization","volume":"3","author":"Gao","year":"2013","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.ijpharm.2021.120548_b0055","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpharm.2021.120548_b0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3389\/fimmu.2017.01001","article-title":"Therapeutic antibodies against intracellular tumor antigens","volume":"8","author":"Trenevska","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpharm.2021.120548_b0065","first-page":"852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mole. Biol. Int."},{"key":"10.1016\/j.ijpharm.2021.120548_b0070","doi-asserted-by":"crossref","unstructured":"Hasmann, 2013, Chapter 9 \u2013 Targeting HER2 by monoclonal antibodies for cancer therapy. In: Ganellin, R., Roberts, S., Jefferis, R., (Eds.), Introduction to Biological and Small Molecule Drug Research and Development, Elsevier, Oxford, pp. 283\u2013305.","DOI":"10.1016\/B978-0-12-397176-0.00009-1"},{"issue":"10","key":"10.1016\/j.ijpharm.2021.120548_b0075","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ijpharm.2021.120548_b0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14737140.2018.1477596","article-title":"Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects","volume":"18","author":"Brand\u00e3o","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"15_suppl","key":"10.1016\/j.ijpharm.2021.120548_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e11598","article-title":"Low-dose doxorubicin combined with trastuzumab in HER2-positive metastatic breast cancer: a single institution experience","volume":"32","author":"Lohman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ijpharm.2021.120548_b0090","first-page":"3670","article-title":"Natural products: a continuing source of novel drug leads","volume":"1830","author":"Cragg","year":"2013","journal-title":"BBA"},{"issue":"16","key":"10.1016\/j.ijpharm.2021.120548_b0095","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.18632\/oncotarget.23898","article-title":"Fucoidan-coated CuS nanoparticles for chemo-and photothermal therapy against cancer","volume":"9","author":"Jang","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ijpharm.2021.120548_b0100","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2174\/1871520617666171121125845","article-title":"A comparison of fucoidan conjugated to paclitaxel and curcumin for the dual delivery of cancer therapeutic agents","volume":"18","author":"Phan","year":"2019","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"8","key":"10.1016\/j.ijpharm.2021.120548_b0105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/03639045.2017.1318895","article-title":"Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells","volume":"43","author":"Jiang","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"16","key":"10.1016\/j.ijpharm.2021.120548_b0110","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2217\/nnm-2018-0004","article-title":"Gemcitabine delivered by fucoidan\/chitosan nanoparticles presents increased toxicity over human breast cancer cells","volume":"13","author":"Oliveira","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijpharm.2021.120548_b0115","first-page":"1977","article-title":"Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab","volume":"6","author":"Yousefpour","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2021.120548_b0120","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.2147\/IJN.S198552","article-title":"Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer","volume":"14","author":"Naruphontjirakul","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2021.120548_b0125","doi-asserted-by":"crossref","first-page":"115206","DOI":"10.1016\/j.carbpol.2019.115206","article-title":"Doxorubicin\/cisplatin co-loaded hyaluronic acid\/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer","volume":"225","author":"Wang","year":"2019","journal-title":"Carbohydr. Polym."},{"issue":"16","key":"10.1016\/j.ijpharm.2021.120548_b0130","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1021\/acsami.8b01432","article-title":"Interleukin-6 neutralization by antibodies immobilized at the surface of polymeric nanoparticles as a therapeutic strategy for arthritic diseases","volume":"10","author":"Lima","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"17","key":"10.1016\/j.ijpharm.2021.120548_b0135","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.7150\/thno.25025","article-title":"WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma","volume":"8","author":"Gon\u00e7alves","year":"2018","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.ijpharm.2021.120548_b0140","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ijpharm.2021.120548_b0145","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.nano.2011.03.009","article-title":"Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy","volume":"7","author":"Arya","year":"2011","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"issue":"3","key":"10.1016\/j.ijpharm.2021.120548_b0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1208\/s12248-014-9579-6","article-title":"Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM)","volume":"16","author":"Panchal","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2021.120548_b0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","article-title":"DLS and zeta potential \u2013 What they are and what they are not?","volume":"235","author":"Bhattacharjee","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2021.120548_b0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.colsurfb.2018.10.007","article-title":"Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy","volume":"173","author":"Kumar Mehata","year":"2019","journal-title":"Colloids Surf., B"},{"issue":"4","key":"10.1016\/j.ijpharm.2021.120548_b0165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1091\/mbc.e03-08-0596","article-title":"Association with membrane protrusions makes ErbB2 an internalization-resistant receptor","volume":"15","author":"Hommelgaard","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"16","key":"10.1016\/j.ijpharm.2021.120548_b0170","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1242\/jcs.007658","article-title":"Mapping ErbB receptors on breast cancer cell membranes during signal transduction","volume":"120","author":"Yang","year":"2007","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ijpharm.2021.120548_b0175","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.ijpharm.2021.120548_b0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000069315","article-title":"Role of gemcitabine in the treatment of advanced and metastatic breast cancer","volume":"64","author":"Heinemann","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ijpharm.2021.120548_b0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4137\/CMO.S6252","article-title":"Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer","volume":"5","author":"Hayashi","year":"2011","journal-title":"Clin. Med. Insights Oncol."},{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00535-005-1724-7","article-title":"Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial","volume":"41","author":"Sakamoto","year":"2006","journal-title":"J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.ijpharm.2021.120548_b0195","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/ijms17091405","article-title":"In vitro co-culture models of breast cancer metastatic progression towards bone","volume":"17","author":"Arrigoni","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ijpharm.2021.120548_b0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/ijms20040840","article-title":"Targeting tumor microenvironment for cancer therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijpharm.2021.120548_b0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"issue":"5","key":"10.1016\/j.ijpharm.2021.120548_b0210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.breast.2014.06.004","article-title":"Current and future role of neoadjuvant therapy for breast cancer","volume":"23","author":"Untch","year":"2014","journal-title":"The Breast"},{"key":"10.1016\/j.ijpharm.2021.120548_b0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: an overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.ijpharm.2021.120548_b0220","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","article-title":"Breast cancer lung metastasis: Molecular biology and therapeutic implications","volume":"19","author":"Jin","year":"2018","journal-title":"Cancer Biol. Ther."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517321003537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517321003537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:14:17Z","timestamp":1759918457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517321003537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":44,"alternative-id":["S0378517321003537"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120548","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fucoidan\/chitosan nanoparticles functionalized with anti-ErbB-2 target breast cancer cells and impair tumor growth in vivo","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120548"}}